Scroll for more
news Jan 9, 2017

British technology firm becomes first artificial intelligence company to appoint a chief medical officer to accelerate its clinical development

London, 9th January 2017 – BenevolentAI, a leading British artificial intelligence (“AI”) company has appointed Dr. Patrick Keohane as Chief Medical Officer (CMO).  BenevolentAI is the first AI company to have a CMO on its staff.

Patrick will take up the position of CMO of BenevolentBio – a subsidiary of BenevolentAI that applies its unique and disruptive AI technology to accelerate a pipeline of better medicines for patients and to explore further applications for AI in bioscience.  He will work with BenevolentBio’s expanding team of experienced drug discovery scientists, technology experts, and bioscience researchers to rapidly identify and progress novel therapies into early and late stage clinical trials.

Dr. Keohane

With over 20 years of experience, Dr. Keohane trained as a Gastroenterologist in the NHS and worked for the Medical Research Council. He has held senior management positions in Research and Development at Eli Lilly and AstraZeneca, and has worked in the US, Japan and Europe. He joins the Company from Glenmark Pharmaceuticals, where he held the position of Chief Medical Officer.

BenevolentAI

BenevolentAI is a British technology company harnessing the power of AI to enhance and accelerate scientific discovery and innovation.  The Company was founded to explore the application of AI in the field of bioscience and has since diversified its technology for applications across many scientific industries. BenevolentAI’s focus is applying AI where the partnership between scientist and technology can create new discoveries that benefit society and address some of the world’s most pressing challenges.

BenevolentBio, a subsidiary of BenevolentAI, focuses on turning the world’s mass of highly fragmented biomedical knowledge and pharmaceutical R&D data into useable new information and insight.  This validated technology has significantly accelerated the process of drug discovery and development in order to bring new medicines to patients more efficiently.

Prof. Jackie Hunter, CEO of BenevolentBio commented: “Patrick’s appointment fits perfectly with our ethos of integrating scientific expertise and technology to revolutionise the drug development process. He brings extensive experience in the worldwide development of medicines and will play a key part in the development of our strong clinical pipeline.

Ken Mulvany, Founder and Director of BenevolentAI commented: “We have made some ground-breaking progress in AI over the last two years which demonstrates the tangible benefits that our technology can bring, not only in the field of bioscience, but to other critical disciplines and industries of science.  Patrick’s appointment is another concrete example of this significant progress and our ambition to recruit the best minds in science and technology.”

Ends